SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways-Reference-Cited by-同舟云学术

SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways

Published:2020-09 Issue:3 Volume:38 Page:350-365.e7
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Yuan Huairui,Han Ying,Wang Xuege,Li Ni,Liu Qiuli,Yin Yuye,Wang Hanling,Pan Lulu,Li Li,Song Kun,Qiu Tong,Pan Qiang,Chen Qilong,Zhang Guoying,Zang Yi,Tan Minjia,Zhang Jian,Li Qintong,Wang Xiaoming,Jiang Jun,Qin Jun

Funder

National Natural Science Foundation of China

Chinese Academy of Sciences

Ministry of Science and Technology of the People's Republic of China

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference80 articles.

1. The long tail of oncogenic drivers in prostate cancer;Armenia;Nat. Genet.,2018

2. NSD2 is a conserved driver of metastatic prostate cancer progression;Aytes;Nat. Commun.,2018

3. Comprehensive characterization of cancer driver genes and mutations;Bailey;Cell,2018

4. Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation;Baubec;Nature,2015

5. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer;Beltran;Nat. Med.,2016

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A literature review on signaling pathways of cervical cancer cell death-apoptosis induced by Traditional Chinese Medicine;Journal of Ethnopharmacology;2024-11

2. Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers;Nature Cancer;2024-09-06

3. Circulating tumor cells: from new biological insights to clinical practice;Signal Transduction and Targeted Therapy;2024-09-02

4. Phase Separation of Chromatin Structure-related Biomolecules: A Driving Force for Epigenetic Regulations;Current Protein & Peptide Science;2024-09

5. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies;European Journal of Pharmacology;2024-09